HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy
In this study we try to increase the radiation dose, while reducing or keeping the radiation schedule below 4 weeks.
The study hypothesis is that it is feasible to administer hyperfractionated accelerated radiotherapy to patients with inoperable or locally advanced non small cell lung cancer.
|Non-Small-Cell Lung Carcinoma||Procedure: dose escalation (radiotherapy treatment schedule)||Phase 1 Phase 2|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Accelerated Conformal Radiotherapy in Patients With Inoperable Non-Small Cell Lung Cancer.|
- acute toxicity
- late toxicity
|Study Start Date:||December 2001|
|Study Completion Date:||December 2007|
|Primary Completion Date:||December 2007 (Final data collection date for primary outcome measure)|
Non-small cell lung cancer is still the most common cancer and the main cause of cancer death. Treatment of choice for these patients is often radiotherapy, which results in an overall 5-year survival rate between 5 and 10%. The addition of chemotherapy improves survival by a few percentages and is therefore considered standard treatment for patients with stage III disease.
However, several factors have been identified that have an impact on the local control but also on survival.
- There is a dose-effect relationship. A higher dose results in a better survival rate. However, higher radiation doses are currently not delivered with conventional radiation due to the tolerance of normal tissue.
- The time factor plays an important role in radiotherapy. Prolonging the overall treatment time decreases the outcome of radiotherapy. Radiobiological modelling of data shows that the overall treatmetn time (OTT) should be kept below 4 weeks. Results from studies support this conclusion.
So, probably the best results will be achieved when a very high radiation dose can be delivered within 4 weeks, without severally damaging normal tissue.
In order to achieve this goal, an hyperfractionated accelerated treatment regimen together with a technically very advanced radiation technique to avoid as much normal tissue as possible, will be used in this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00181506
|Maastircht Radiation Oncology|
|Heerlen, Limburg, Netherlands, 6411 PC|
|Principal Investigator:||Rinus Wanders, MD||Maastricht Radiation Oncology (MAASTRO clinic)|